JOURNAL DESCRIPTION
The Medical Radiology and Radiation Safety journal ISSN 1024-6177 was founded in January 1956 (before December 30, 1993 it was entitled Medical Radiology, ISSN 0025-8334). In 2018, the journal received Online ISSN: 2618-9615 and was registered as an electronic online publication in Roskomnadzor on March 29, 2018. It publishes original research articles which cover questions of radiobiology, radiation medicine, radiation safety, radiation therapy, nuclear medicine and scientific reviews. In general the journal has more than 30 headings and it is of interest for specialists working in thefields of medicine¸ radiation biology, epidemiology, medical physics and technology. Since July 01, 2008 the journal has been published by State Research Center - Burnasyan Federal Medical Biophysical Center of Federal Medical Biological Agency. The founder from 1956 to the present time is the Ministry of Health of the Russian Federation, and from 2008 to the present time is the Federal Medical Biological Agency.
Members of the editorial board are scientists specializing in the field of radiation biology and medicine, radiation protection, radiation epidemiology, radiation oncology, radiation diagnostics and therapy, nuclear medicine and medical physics. The editorial board consists of academicians (members of the Russian Academy of Science (RAS)), the full member of Academy of Medical Sciences of the Republic of Armenia, corresponding members of the RAS, Doctors of Medicine, professor, candidates and doctors of biological, physical mathematics and engineering sciences. The editorial board is constantly replenished by experts who work in the CIS and foreign countries.
Six issues of the journal are published per year, the volume is 13.5 conventional printed sheets, 88 printer’s sheets, 1.000 copies. The journal has an identical full-text electronic version, which, simultaneously with the printed version and color drawings, is posted on the sites of the Scientific Electronic Library (SEL) and the journal's website. The journal is distributed through the Rospechat Agency under the contract № 7407 of June 16, 2006, through individual buyers and commercial structures. The publication of articles is free.
The journal is included in the List of Russian Reviewed Scientific Journals of the Higher Attestation Commission. Since 2008 the journal has been available on the Internet and indexed in the RISC database which is placed on Web of Science. Since February 2nd, 2018, the journal "Medical Radiology and Radiation Safety" has been indexed in the SCOPUS abstract and citation database.
Brief electronic versions of the Journal have been publicly available since 2005 on the website of the Medical Radiology and Radiation Safety Journal: http://www.medradiol.ru. Since 2011, all issues of the journal as a whole are publicly available, and since 2016 - full-text versions of scientific articles. Since 2005, subscribers can purchase full versions of other articles of any issue only through the National Electronic Library. The editor of the Medical Radiology and Radiation Safety Journal in accordance with the National Electronic Library agreement has been providing the Library with all its production since 2005 until now.
The main working language of the journal is Russian, an additional language is English, which is used to write titles of articles, information about authors, annotations, key words, a list of literature.
Since 2017 the journal Medical Radiology and Radiation Safety has switched to digital identification of publications, assigning to each article the identifier of the digital object (DOI), which greatly accelerated the search for the location of the article on the Internet. In future it is planned to publish the English-language version of the journal Medical Radiology and Radiation Safety for its development. In order to obtain information about the publication activity of the journal in March 2015, a counter of readers' references to the materials posted on the site from 2005 to the present which is placed on the journal's website. During 2015 - 2016 years on average there were no more than 100-170 handlings per day. Publication of a number of articles, as well as electronic versions of profile monographs and collections in the public domain, dramatically increased the number of handlings to the journal's website to 500 - 800 per day, and the total number of visits to the site at the end of 2017 was more than 230.000.
The two-year impact factor of RISC, according to data for 2017, was 0.439, taking into account citation from all sources - 0.570, and the five-year impact factor of RISC - 0.352.
Medical Radiology and Radiation Safety. 2022. Vol. 67. № 4
Peculiarities of Human Tumor HeLa Cells Surviving and Giving
a Stable Growth After Acute X-ray Irradiation
D.V. Guryev1, 2, A.A. Tsishnatti1, 3, S.M. Rodneva1, Yu.A. Fedotov1, 2,
D.V. Molodtsova1, T.M. Blokhinа1, 2, E.I. Yashkina1, 2,
A.N. Osipov1, 2
1A.I. Burnasyan Federal Medical Biophysical Center, Moscow, Russia
2N.N. Semenov Federal Research Center for Chemical Physics, Moscow, Russia
3National Research Nuclear University MEPHI, Moscow, Russia
Contact person: D.V. Guryev, e-mail: This email address is being protected from spambots. You need JavaScript enabled to view it.
ABSTRACT
Purpose: The evaluation of the repair efficiency of DNA double-strand breaks (DSB), proliferative activity and the yield of cytogenetic disorders in human tumor HeLa cells which survived and gave stable growth after acute irradiation at a dose of 15 Gy.
Material and methods: HeLa human tumor cell line (cervical carcinoma) was used. Cells were irradiated on an X-ray biological installation RUST-M1 (Russia), equipped with two X-ray emitters, at a dose rate of 0.85 Gy / min, a voltage of 200 kV, a total current of 10 mA, and a 1.5 mm Al filter. To obtain clones of surviving cells (HeLaRR), after acute irradiation at a dose of 15 Gy, cell cultures were incubated under standard CO2 incubator conditions (37 °C, 5 % CO2) for several weeks until well proliferating cells were obtained. Immunocytochemical staining of the foci of the phosphorylated H2AX protein (γH2AX) was used to quantitatively evaluate the residual foci of DNA DSB repair. The micronuclei number was assessed in cytochalasin-B cytokinesis-blocked binucleated cells stained with acridine orange with luminescence microscopy. The doubling time of the cell population was analyzed by the cell growth curves obtained by daily cell counting for five days. The cell cycle stages distribution was assessed by flow cytometry using the propidium iodide dye. All quantitative indicators of the studies were processed using the Student’s t-test for independent samples and the Kolmogorov – Smirnov test.
Results: It was revealed that acute irradiation at a high dose leads to the selection of cells with a higher reparative capacity which is confirmed by the low yield of residual foci of DNA DSB repair and MN after testing irradiation at doses of 5 and 10 Gy. A significant decrease in the proliferative activity of cells that survived after acute X-ray irradiation at a dose of 15 Gy was revealed. The doubling time of the population of unirradiated cells at the stage of exponential growth was ~18 hours while for cells that survived after irradiation at a dose of 15 Gy ~42 hours. A change in the cell cycle phases distribution was observed.
Conclusion: Thus, acute irradiation at a high dose leads to the selection of cells with a higher reparative capacity which is confirmed by the low yield of residual γH2AX foci and MN after testing irradiation at doses of 5 and 10 Gy. The decrease in proliferative activity was accompanied by a change in the cell cycle phases distribution.
Keywords: HeLa, γH2AX, micronuclei, proliferation, residual foci, DNA double-strand breaks, Х-ray
For citation: Guryev DV, Tsishnatti AA, Rodneva SM, Fedotov YuA, Molodtsova DV, Blokhinа TM, Yashkina E.I., Osipov AN. Peculiarities of Human Tumor HeLa Cells Surviving and Giving a Stable Growth After Acute X-ray Irradiation. Medical Radiology and Radiation Safety. 2022;67(4):5–9. (In Russian). DOI:10.33266/1024-6177-2022-67-4-5-9
References
1. Dean M., Fojo T., Bates S.. Tumour Stem Cells and Drug Resistance. Nat. Rev. Cancer. 2005;5;4:275-284.
2. Alhaddad L., Pustovalova M., Blokhina T., Chuprov-Netochin R., Osipov A.N., Leonov S. IR-Surviving NSCLC Cells Exhibit Different Patterns of Molecular and Cellular Reactions Relating to the Multifraction Irradiation Regimen and p53-Family Proteins Expression. Cancers. 2021;13;11:2669.
3. Pustovalova M., Alhaddad L., Smetanina N., Chigasova A., Blokhina T., Chuprov-Netochin R., et al. The p53–53BP1-Related Survival of A549 and H1299 Human Lung Cancer Cells after Multifractionated Radiotherapy Demonstrated Different Response to Additional Acute X-ray Exposure. International Journal of Molecular Sciences. 2020;21;9:3342.
4. Almendro V., Marusyk A., Polyak K. Cellular Heterogeneity and Molecular Evolution in Cancer. Annu. Rev. Pathol. 2013;8:277-302.
5. De Sousa E.M.F., Vermeulen L., Fessler E., Medema J.P. Cancer Heterogeneity-a Multifaceted View. EMBO Rep. 2013;14;8:686-695.
6. Butof R., Dubrovska A., Baumann M.. Clinical Perspectives of Cancer Stem Cell Research in Radiation Oncology. Radiother Oncol. 2013;108;3:388-396.
7. Peitzsch C., Kurth I., Kunz-Schughart L., Baumann M., Dubrovska A.. Discovery of the Cancer Stem Cell Related Determinants of Radioresistance. Radiother Oncol. 2013;108;3:378-387.
8. Krause M., Dubrovska A., Linge A., Baumann M. Cancer Stem Cells: Radioresistance, Prediction of Radiotherapy Outcome and Specific Targets for Combined Treatments. Adv. Drug. Deliv. Rev. 2017;109:63-73.
9. Pustovalova M., Alhaddad L., Blokhina T., Smetanina N., Chigasova A., Chuprov-Netochin R., et al. The CD44high Subpopulation of Multifraction Irradiation-Surviving NSCLC Cells Exhibits Partial EMT-Program Activation and DNA Damage Response Depending on Their p53 Status. International Journal of Molecular Sciences. 2021;22;5:2369.
10. Peitzsch C., Tyutyunnykova A., Pantel K., Dubrovska A. Cancer Stem Cells: The Root of Tumor Recurrence and Metastases. Semin Cancer Biol. 2017;44:10-24.
11. International Atomic Energy Agency. Cytogenetic Analysis for Radiation Dose Assessment: a Manual. Vienna, International Atomic Energy Agency, 2001. 127 p.
12. Siddiqui M.S., Francois M., Fenech M.F., Leifert W.R. Persistent GammaH2AX: A Promising Molecular Marker of DNA Damage and Aging. Mutat. Res. Rev. Mutat. Res. 2015;766:1-19.
13. Sorokin M., Kholodenko R., Grekhova A., Suntsova M., Pustovalova M., Vorobyeva N., et al. Acquired Resistance to Tyrosine Kinase Inhibitors May be Linked with the Decreased Sensitivity to X-Ray Irradiation. Oncotarget. 2017;9;4:5111-5124.
14. Babayan N., Vorobyeva N., Grigoryan B., Grekhova A., Pustovalova M., Rodneva S., et al. Low Repair Capacity of DNA Double-Strand Breaks Induced by Laser-Driven Ultrashort Electron Beams in Cancer Cells. International Journal of Molecular Sciences. 2020;21;24:9488.
15. Banáth J.P., Klokov D., MacPhail S.H., Banuelos C.A., Olive P.L. Residual γH2AX Foci as an Indication of Lethal DNA Lesions. BMC Cancer. 2010;10;1.
16. Raavi V., Perumal V., Paul S.F.D. Potential Application of γ-H2AX as a Biodosimetry Tool for Radiation Triage. Mutation Research/Reviews in Mutation Research. 2021;787:108350.
17. Vaurijoux A., Voisin P., Freneau A., Barquinero J.F., Gruel G. Transmission of Persistent Ionizing Radiation-Induced Foci Through Cell Division in Human Primary Cells. Mutat Res. 2017;797-799:15-25.
18. Akudugu J.M., Theron T., Serafin A.M., Bohm L. Influence of DNA Double-Strand Break Rejoining on Clonogenic Survival and Micronucleus Yield in Human Cell Lines. Int. J. Radiat. Biol. 2004;80;2:93-104.
19. Akudugu J.M., Bohm L. Micronuclei and Apoptosis in Glioma and Neuroblastoma Cell Lines and Role of Other Lesions in the Reconstruction of Cellular Radiosensitivity. Radiat Environ Biophys. 2001;40;4:295-300.
20. Liu C., Nie J., Wang R., Mao W. The Cell Cycle G2/M Block Is an Indicator of Cellular Radiosensitivity. Dose-Response. 2019;17;4:155932581989100.
PDF (RUS) Full-text article (in Russian)
Conflict of interest. All authors made the same contribution to the conception, design, conduction, date analysis of the investigation and the creation of the text of the article.
Financing. The work was conducted by the research state task «Development of approaches to reduce the radioresistance of tumor stem cells» (АААА-А19-119122000097-6).
Contribution. Article was prepared with equal participation of the authors.
Article received: 17.01.2022. Accepted for publication: 15.03.2022.